Neurofilament light chain as a serum marker for cerebral small vessel disease (P2.096)

Conclusions:In conclusion, serum NFL levels were strongly related to MR-imaging markers as well as clinical and cognitive symptoms of SVD. For disability and dependence there was an added value of serum NFL levels beyond imaging markers. Potentially, serum NFL may serve as a marker of disease burden and progression in SVD.Disclosure: Dr. Duering has nothing to disclose. Dr. Tiedt has nothing to disclose. Dr. Baykara has nothing to disclose. Dr. Lyrer has received personal compensation for activities with Boehringer Ingelheim, Switzerland and Bayer Healthcare, Switzerland as a member of the scientific advisory board. Dr. Engelter has nothing to disclose. Dr. Gesierich has nothing to disclose. Dr. Achmueller has nothing to disclose. Dr. Barro has nothing to disclose. Dr. Adam has nothing to disclose. Dr. Ewers has nothing to disclose. Dr. Dichgans has nothing to disclose. Dr. Kuhle holds stock and/or stock options in Bayer (Schweiz) AG, Genzyme, Novartis, Protagen AG, and Roche. Dr. Peters has received personal compensation for activities with Boehringer, BMS/Pfizer, and Bayer for serving on a scientific advisory board.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Duering, M., Tiedt, S., Baykara, E., Lyrer, P., Engelter, S., Gesierich, B., Achmueller, M., Barro, C., Adam, R., Ewers, M., Dichgans, M., Kuhle, J., Peters, N. Tags: Vascular Disease and Dementia Source Type: research